Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Optina Reports a US$2.1M Investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an up to US$2.1M investment from the Alzheimer’s Drug Discovery Foundation (ADDF). The investment will be made through the ADDF’s Diagnostics Accelerator, a collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease.

This funding comes on the tail of closing an oversubscribed Series-A round led by DigitalDx Ventures including Boehringer Ingelheim Venture Fund, Desjardins, Zoic Capital as well as other investors.

  • This new funding will support Optina’s pivotal study for the FDA regulatory submission of the awAIrTM cerebral amyloid status test for Alzheimer’s disease detection, aligning Optina’s platform with novel therapeutic approvals
  • Specifically, this new financing will enable Optina to expand its pivotal study’s cohort size
  • Optina’s clinical study will take place across 5 sites in USA, Canada and Europe

Optina’s Retinal Deep PhenotypingTM platform obtained the FDA Breakthrough Device Designation status in 2019 for its first indication, a non-invasive and more accessible test to improve diagnosis accuracy and the management of patients undergoing evaluation for Alzheimer’s disease (AD) and received 501(k) clearance for its hyper-spectral Optina-4CTM camera in 2020.

The primary focus of the investment from the ADDF’s Diagnostics Accelerator is to support the pivotal study for Optina’s awAIr TM cerebral amyloid status test when AD is suspected. These funds will also be used to accelerate the deployment of additional clinical study sites with the installation of Optina’s Retinal Deep PhenotypingTM platform at further leading institutions.

It is now broadly acknowledged that one key step to improving brain health in the overall medical field lies in a readily accessible, non-invasive, precise, and objective diagnostic test for patients suffering from and/or at risk of cognitive decline. Thus, targeted intervention can take place as early as possible, ideally prior to brain damage/memory loss, and potentially alter the course of the disease. Alzheimer’s detection, and targeted differentiation from other illnesses associated with memory loss, is one part of Optina’s broader brain health platform unlocking the secrets of multiple systemic diseases.

“The ADDF created the Diagnostics Accelerator to support research into promising biomarkers that will play a crucial role in research, diagnosis, and treatment of Alzheimer’s disease. A simple eye scan, such as the technology developed by Optina, has the potential to help with early, non-invasive detection of Alzheimer’s, which is essential to getting the right patients into trials and moving research forward,” said Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF.

“Optina is proud to have been chosen for the ADDF’s Diagnostics Accelerator initiative. We are confident that we can have an impact and change the lives of millions of patients in the future. We are already putting this investment to work with the start of our pivotal study, thanks to all of the participants, their families and experts around the world supporting our novel approach to on-site/same-day results using noninvasive digital data capture (1-second eye scan) which greatly simplifies both the diagnostic process and the patient’s journey,” added David Lapointe, CEO of Optina Diagnostics

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine